Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018102314) POLYMORPHIC FORM OF SEPIAPTERIN
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/102314 International Application No.: PCT/US2017/063515
Publication Date: 07.06.2018 International Filing Date: 28.11.2017
IPC:
C07D 475/04 (2006.01) ,C07D 475/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
475
Heterocyclic compounds containing pteridine ring systems
02
with an oxygen atom directly attached in position 4
04
with a nitrogen atom directly attached in position 2
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
475
Heterocyclic compounds containing pteridine ring systems
Applicants:
CENSA PHARMACEUTICALS INC. [US/US]; 65 William Street Suite #200t Wellesley, MA 02481, US
Inventors:
LEVY, Daniel, E.; US
YOSHINO, Hiroshi; JP
KOMODA, Taichi; JP
MATSUMOTO, Takayoshi; JP
KISHIMOTO, Kaito; JP
MURATA, Shunichi; JP
SHIRO, Yuichi; JP
Agent:
MCDONALD, J., Cooper; US
Priority Data:
62/427,68629.11.2016US
Title (EN) POLYMORPHIC FORM OF SEPIAPTERIN
(FR) FORME POLYMORPHE DE SÉPIAPTÉRINE
Abstract:
(EN) Disclosed is a crystalline form of sepiapterin, a method of preparing the crystalline form, pharmaceutical compositions containing the crystalline form, and a method for treating patients with a disease associated with low intracellular BH4 levels or with dysfunction of various BH4 dependent metabolic pathways, which involves administering to the patient an effective amount of the crystalline form.
(FR) L'invention concerne une forme cristalline de sépiaptérine, un procédé de préparation de la forme cristalline, des compositions pharmaceutiques contenant la forme cristalline, et un procédé de traitement de patients atteints d'une maladie associée à de faibles niveaux de BH4 intracellulaire ou avec un dysfonctionnement de diverses voies métaboliques dépendant de BH4, qui consiste à administrer au patient une quantité efficace de la forme cristalline.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)